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Abstract Inflammatory bowel disease (IBD) is a chronic
and relapsing inflammatory disorder of the gut. Although
the precise cause of IBD remains unknown, the most
accepted hypothesis of IBD pathogenesis to date is that
an aberrant immune response against the gut microbiota
is triggered by environmental factors in a genetically
susceptible host. The advancement of next-generation
sequencing technology has enabled identification of var-
ious alterations of the gut microbiota composition in
IBD. While some results related to dysbiosis in IBD
are different between studies owing to variations of sam-
ple type, method of investigation, patient profiles, and
medication, the most consistent observation in IBD is
reduced bacterial diversity, a decrease of Firmicutes,
and an increase of Proteobacteria. It has not yet been
established how dysbiosis contributes to intestinal in-
flammation. Many of the known IBD susceptibility genes
are associated with recognition and processing of bacte-
ria, which is consistent with a role of the gut microbiota
in the pathogenesis of IBD. A number of trials have
shown that therapies correcting dysbiosis, including fecal
microbiota transplantation and probiotics, are promising
in IBD.
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Introduction
Inflammatory bowel disease (IBD) is a disorder characterized
by chronic and relapsing intestinal inflammation and is mainly
defined as either ulcerative colitis (UC) or Crohn’s disease
(CD). Although the cause of IBD remains unknown, genetic
background is considered to be involved in the pathophysiol-
ogy of IBD because a number of disease susceptibility genes
have been identified. The rapid increase in the incidence of
IBD, however, cannot be explained by genetic factors alone,
and environmental factors must also be essential to its
development.
The involvement of the gut microbiota in the patho-
physiology of IBD has recently been highlighted. Several
lines of evidence suggest an essential role of the gut
microbiota in intestinal inflammation. (1) In murine
models of IBD such as IL-10-deficient mice and the
CD45Rbhigh transfer model, where transferred naïve help-
er T cells cause microbiota-dependent intestinal inflam-
mation in immune-deficient recipients such as Rag2−/−
mice, germ-free animals do not develop colitis. (2) Diver-
sion of the fecal stream ameliorates intestinal inflamma-
tion in CD [1]. (3) Antibiotics are, to a certain degree,
effective for the treatment of IBD [2]. (4) Antibiotics such
as metronidazole and ciprofloxacin are also effective for
anal lesions and prevention of postoperative recurrence in
CD [3]. (5) Many of the reported IBD susceptibility genes
are associated with recognition and processing of mi-
crobes [4].
Given these observations, the most accepted hypothesis of
IBD pathogenesis to date is that an aberrant immune response
against the gut microbiota is triggered by environmental fac-
tors in a genetically susceptible host. In this review, we will
discuss abnormalities of the gut microbiota observed in IBD,
their contribution to the pathogenesis of IBD, and related
therapeutic applications.
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Alteration of the gut microbiota in IBD
Dysbiosis
The host provides a nutrient-rich environment and residence
for the gut bacteria, and in turn, they contribute to the host by
producing short-chain fatty acids and essential vitamins. This
mutual relationship between the host and the gut bacteria is
called symbiosis. Recent advancement of next-generation se-
quencing techniques has enabled culture-independent analysis
of the gut microbiota, revealing that an altered balance of the
gut microbiota constituents, rather than specific pathogens, is
involved in the pathophysiology of several diseases. This shift
in the balance of the gut microbiota is referred to as dysbiosis.
More than 90 % of the human gut microbiota is composed
of four major phyla. The Firmicutes (49–76 %) and
Bacteroidetes (16–23 %) phyla dominate, followed to a much
less extent by the Proteobacteria and Actinobacteria phyla [5,
6]. The Firmicutes phylum is mainly composed of the
Clostridium XIVand IV groups.
Various alterations of the gut microbiota have been report-
ed in IBD patients (Table 1). Most studies have shown re-
duced diversity of the gut microbiota in IBD patients [6–9].
The most consistent observations of altered composition of
the gut microbiota in IBD patients are a reduction in
Firmicutes and an increase in Proteobacteria [6, 7, 10–12].
The reduced diversity of the gut microbiota observed in IBD
patients is largely due to a decline in the diversity of
Firmicutes. Among Firmicutes, a decrease in the Clostridium
leptum groups, especially Faecalibacterium prausnitzii, has
been reported in many studies [7, 13, 14]. Results related to
Enterobacteriaceae, Bacteroides, Bifidobacteria species,
Lactobacillus species, and Escherichia coli are not consistent
among studies [15, 16]. Various factors may explain the
between-study discrepancies: (1) sample source (biopsy or
stool), (2) sampling location (inflammatory or noninflamma-
tory sites), (3) disease activity (active or quiescent), (4) med-
ication, (5) diet, (6) age, (7) smoking, and (8) methods used to
analyze the microbiota.
While the gut microbiota in healthy subjects shows little
temporal change, the gut microbiota in IBD patients is unsta-
ble. The composition of the gut microbiota differs between
active and quiescent stages. Furthermore, a study that longi-
tudinally examined the gut microbiota in IBD patients for a
year demonstrated that the gut microbiota was unstable even
in UC patients in remission [17]. Before relapse of UC,
normal anaerobic bacteria such as Bacteroides, Escherichia,
Eubacterium, Lactobacillus, and Ruminococcus are decreased
and the diversity of the gut microbiota is also reduced [18]. In
CD patients, dysbiosis is observed even in patients with
remission. Medication also affects the composition of the
gut microbiota. Mesalazine, for example, reduces the total
bacterial number to almost half [19]. Bowel rest, which is a
treatment option in CD, changes the composition of the gut
microbiota. Antibiotics dramatically amplify the dysbiosis of
CD [20].
The distribution of the gut microbiota should be taken into
account when interpreting dysbiosis. For example, the com-
position of the microbiota is significantly different between
fecal and mucosal samples [5, 21]. Mucosal samples are
reported to be superior in order to detect dysbiosis [20]. The
mucosa-associated microbiota is increased in IBD compared
with healthy subjects [22, 23]. It is tempting to speculate that
the mucosa-associated microbiota is physiologically more
important in IBD than luminal microbiota because of the close
contact of mucosa-associated bacteria with the intestinal sur-
face. It has also been reported that the gut microbiota is
different in the same individual between inflammatory and
noninflammatory sites [24]. The dysbiosis observed in nonin-
flammatory sites may be more representative of a causative
composition because the dysbiosis observed in inflammatory
sites may be affected by inflammation.
It remains controversial whether dysbiosis is a cause or
consequence of intestinal inflammation in IBD. Comparison
of the gut microbiota composition of IBD patients with that of
their unaffected relatives, who are likely to share genetic and
environmental background, is useful to provide evidence rel-
evant to this fundamental question. Compositional change of
the gut microbiota was not consistent between UC patients
and their unaffected twins [25]. In contrast, a decrease in
F. prausnitzii was reported to be observed in both UC patients
and their first-grade relatives [26]. Unaffected relatives of CD
patients also had dysbiosis, although it was different from the
dysbiosis observed in CD patients [27]. Furthermore, it was
reported that the genetic status of NOD2 and ATG18L genes,
which are two major CD susceptibility genes, was associated
with alteration of the gut microbiota [28]. These results sug-
gest that dysbiosis is caused by genetic and environmental
factors, rather than being a consequence of inflammation.
There have been attempts to utilize dysbiosis as a diagnos-
tic tool or biomarker [9]. To date, there are no microbial
constituents specific to UC or CD, because interindividual
variations are much larger than inter-disease differences [6].
Several studies have suggested the possibility of using the gut
microbiota as a biomarker. Firmicutes, for example, was in-
creased in UC patients who responded tomesalazine [19]. The
relapse rate was lower in postoperative CD patients who had a
similar composition of gut microbiota to healthy controls than
in those with dysbiosis [29]. In the largest CD microbiota
cohort so far, comparing 447 newly diagnosed pediatric CD
patients with 221 healthy controls, Gevers et al. proposed a
“dysbiosis index,” which was shown to be associated with
clinical disease severity assessed using the Pediatric Crohn’s
Disease Index [20]. They also reported that profiles of the gut
microbiota were able to be utilized as a diagnostic marker of
CD and were also useful to predict the severity at 6 months.
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This report encourages further efforts to use gut microbial
profiles as a diagnostic tool or biomarker for disease activity,
prognosis, and response to treatment.
Specific bacteria associated with IBD
There have been no specific pathogens yet identified that
fulfill Koch’s postulates. There are, however, several specific
bacteria that are associated with IBD. Mycobacterium avium
subspecies paratuberculosis (MAP) causes chronic granulo-
matous ileitis (Johne’s disease) in cattle and sheep, which
shares some pathological features with CD. In addition, be-
causeMAP has been found in commercial milk, it is suspected
as a causative pathogen of CD. MAP was detected in CD
patients using mucosal PCR, and the positive rates of serum
anti-MAP antibody were higher in CD patients than in healthy
controls or UC patients [30]. However, a clinical trial of a 2-
year administration of antituberculosis drugs to CD patients
showed no efficacy [31]. Adhesive-invasive E. coli (AIEC),
which can adhere to and invade the intestinal epithelial cells,
colonize the ileal mucosa of CD [32]. AIEC also replicate in
macrophages and stimulate TNFα production from
macrophages. It was observed that Fusobacterium varium
attaches to inflamed regions in UC and invades the mucosa
at ulcers [33]. Serum titers for anti-F. varium antibodies were
higher in UC patients compared with healthy controls [34].
F. varium produces butyrate, and rectal administration of
butyrate has been shown to cause mucosal damage in mice
[35]. The pathological consequence of butyrate production by
F. varium, however, needs to be examined more extensively
because butyrate has diverse effects on the intestinal homeo-
stasis including Treg induction in the gut and energy supply to
the intestinal epithelial cells. The combination therapy of
amoxicillin, tetracycline, and metronidazole (to which
F. varium is sensitive) for 2 weeks showed efficacy in active
UC patients, suggesting the possible pathogenic role of
F. varium [36].
The role of the gut microbiota in IBD revealed
by susceptibility genes
The association of IBD susceptibility genes with bacteria has
recently been highlighted. The development of the genome-
wide association study has contributed greatly to the
Table 1 Metagenomic analysis of the gut microbiota in inflammatory bowel disease
Sample
source
Sample no. Diversity Bacterial
no.
Firmicutes Bacteroidetes Actinobacteria Proteobacteria Ref.
CD UC HC
Stool 6 – 6 ↓ in CD ↓ in CD → in IBD [7]
Biopsy 6 5 5 ↓ in CD ↑ in CD ↑ in IBD ↑ in CD [10]
Surgical
tissue
35 55 34 ↓ in IBD ↓ Lachnospiraceae ↓ in IBD ↑ Bifidobacteriaceae
in cCD
↑ in IBD [6]
↑ Bacillus ↑ Coriobacteriaceae
in cCD
Stool 29 16 35 ↓ in CD ↓ in CD ↑ in cCD, ↓ in iCD ↑ Enterobacteriaceae
in CD
[8]
↑ Ruminococcaceae in cCD
↓ Ruminococcaceae in iCD
Biopsy 6 6 5 ↓ in IBD ↓ in CD ↓ in IBD ↑ in IBD ↑ Enterobacteriaceae
in CD
[24]
→ F. prausnitzii in IBD






16 16 32 ↓ in IBD ↓ in IBD ↑ in IBD [9]
↓ F. prausnitzii in IBD
Stool 21 34 21 → ↓ C. coccoides and
C. leptum in IBD
↑ Bifidobacterium in
UC
↑ E. coli in CD [14]
↑ Lactobacillus in CD
↓F. prausnitzii in IBD
Biopsy 29 15 21 ↓ in IBD ↓ C. coccoides in CD ↑ in IBD ↓ Bifidobacteriaceae
in CD
↑ E. coli in IBD [14]
↓ C. leptum in IBD
↑ Lactobacillus in CD
↓ F. prausnitzii in IBD
Biopsy and
stool
447 – 221 ↓ in CD ↓ Clostridiales in CD ↓ in CD ↑ Enterobacteriaceae
in CD
[20]
CD Crohn’s disease, UC ulcerative colitis, IBD inflammatory bowel disease, iCD ileal CD, cCD colonic CD
Semin Immunopathol (2015) 37:47–55 49
identification of more than 160 IBD susceptibility genes to
date [4]. The physiological functions of these genes are cate-
gorized into several groups relating to (1) acquired immunity
(IL23R, IL12B, JAK2, STAT3), (2) bacterial recognition and
processing (NOD2/CARD15), (3) autophagy (ATG16L,
IRGM, ATG5), and (4) mucosal barrier (ECM1, CDH1,
LAMB1) [37]. Many of the CD susceptibility genes are asso-
ciated with bacterial recognition and processing, and many of
the UC susceptibility genes are related to mucosal barrier
function, suggesting that impaired handling of bacteria or
disruption of the mucosal barrier function leads to breakdown
of tolerance against the commensal bacterial in the gut in CD
and UC, respectively.
NOD2/CARD15was the first reported CD susceptible gene
and shows the strongest association with CD. The function of
the NOD2 protein has been extensively studied. NOD2 is an
intracellular receptor for muramyl dipeptide (MDP), a com-
ponent of the cell wall of gram-positive bacteria, and is
expressed in intestinal epithelial cells and monocytes/macro-
phages. While Nod2-deficient mice do not develop spontane-
ous colitis, the bacterial load in the gut is increased in these
mice. CD patients with NOD2 mutations demonstrate dimin-
ished production of antimicrobial peptides (AMPs) from
Paneth cells [38] as well as reduced production of the anti-
inflammatory cytokine IL-10 from peripheral mononuclear
cells [39]. NOD2 stimulation with MDP induces autophagy
[40], which regulates replication of intracellular bacteria and is
also involved in bacterial antigen presentation in the infected
cells.
Several autophagy-related genes have also been reported as
CD susceptibility genes. Autophagy is an intracellular process
that is involved in degradation and recycling of proteins when
cells are in starvation. Autophagy is also involved in the
handling of intracellular pathogens. ATG16L is a susceptibil-
ity gene for CD and is essential for autophagosome formation.
Interestingly, it has been shown that NOD1 and NOD2 sense
bacterial invasion into the cell and recruit ATG16L to the site
of bacterial entry, which triggers autophagy. The intracellular
bacteria are then processed through autophagy [40]. This close
association between NOD2 and ATG16L suggests the impor-
tance of this pathway in the pathophysiology of CD.
Studies on IBD susceptibility genes have revealed the
essential role of Paneth cells in CD. Paneth cells reside at
the bottom of the intestinal crypts and produce AMPs. The
important role of Paneth cells in the regulation of the gut
microbiota and the intestinal immune system is shown by
the observation that genetically engineered mice overexpress-
ing α-defensin, one of the AMPs, in intestinal epithelial cells
had a reduced number of segmented filamentous bacteria
(SFB) in the gastrointestinal tract, resulting in impaired
Th17 development in the gut [41]. Abnormalities in the size,
number, and distribution of granules in Paneth cells, which
contain AMPs, have been observed in CD. These
morphological abnormalities were reported to be more fre-
quent in CD patients with NOD2 or ATG16L mutations [42].
Mice harboring the same Atg16l mutation as CD patients
develop similar morphological abnormalities of Paneth cells
after murine Norovirus infection and become susceptible to
dextran sodium sulfate (DSS)-induced colitis [43]. These
results provide a good example of the complex interaction
between a genetic factor and an environmental factor in the
development of intestinal inflammation. Mice deficient in
Xbp1, which is an essential molecule for endoplasmic reticu-
lum stress and is a CD susceptibility gene, also have impaired
autophagy induction in Paneth cells and develop spontaneous
ileitis [44]. These results suggest that autophagy in Paneth
cells is critical for maintaining gut homeostasis, probably
through regulation of the gut microbiota by AMP production.
Impaired Paneth cell function may be an essential element in
the development and perpetuation of intestinal inflammation
in CD.
How does dysbiosis lead to intestinal inflammation?
It is well known that different commensal bacteria induce
distinct types of colitis in IL-10-deficient mice. A mono-
association study, in which a single strain of bacteria was
inoculated into germ-free IL-10-deficient mice, demonstrated
that E. coli induced cecal inflammation,Enterococcus faecalis
induced distal colitis, and Pseudomonas fluorescens did not
cause colitis [45]. It was also reported that the presence of
Helicobacter hepaticus, a species of commensal bacteria,
exacerbated colitis in IL-10-deficient mice. These results
show that alteration of the composition of the gut microbiota
can cause distinct intestinal immune responses even in a host
with the same genetic background, suggesting that dysbiosis
can modulate the immune response in the gut.
Garrett et al. [46] reported that mice deficient in both
Tbx21/T-bet, which is an essential transcription factor for
Th1 differentiation, and Rag, which is indispensable for the
acquired immune system, developed spontaneous UC-like
colitis, which was ameliorated by the administration of anti-
biotics. Importantly, wild-type mice co-housed with colitic T-
bet/Rag double knockout mice also developed similar colitis,
suggesting that a dysbiotic gut microbiota is communicable
and can cause intestinal inflammation without genetic
manipulation.
Functional changes in the gut microbiota resulting from
dysbiosis may be involved in the pathophysiology of IBD.
The number of genes harbored in the gut microbiota is 100
times greater than that in the human genome [5, 47, 48].
Metabolites of the gut microbiota contribute to epithelial cell
function, energy balance, and the immune system of the host.
A metagenomic analysis of the gut microbiota showed a
decrease in genes responsible for carbohydrate and amino
acid metabolism and an increase in those in the oxidative
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stress pathway, in IBD patients [49], raising the possibility that
oxidative stress from the gut microbiota causes intestinal
inflammation in IBD patients. A specific metabolite of the
gut microbiota is also likely to be involved in the pathophys-
iology of IBD. The gut microbiota metabolizes nonabsorptive
dietary fiber and produces short-chain fatty acids such as
butyrate and propionate. Commensal bacteria-derived buty-
rate induces the differentiation of colonic regulatory T cells in
mice [50]. Butyrate is also an important energy source for
intestinal epithelial cells and increases production of mucin
and AMPs [13]. The concentrations of butyrate in feces have
consistently been shown to be decreased in IBD patients.
Consistently, F. prausnitzii, a species of butyrate-producing
bacteria, has also been observed to be decreased in IBD [16].
It is possible that the decreased level of butyrate in the gut
contributes to inducing intestinal inflammation. Another ex-
ample of a functional alteration of the gut microbiota in IBD is
the increase of sulfate-reducing bacteria (SRB) in UC [51].
SRB produce hydrogen sulfide, which is toxic to the intestinal
epithelial cells and can cause mucosal inflammation.
Recent studies have revealed that specific bacteria control
the intestinal immune system. SFB, for example, induce Th17
cells in the murine intestine [52]. Although the human coun-
terpart of SFB has not yet been identified, SFB-like organisms
were observed in six out of six surgical specimens from UC
patients [53]. These SFB-like organisms were not observed in
surgical specimens from CD patients. In non-IBD controls,
SFB-like organisms were observed in three out of six speci-
mens, with a much lower density compared with UC. These
are interesting observations because Th17 cells were reported
to be increased in IBD. The physiological role of these SFB-
like organisms requires further investigation.
The number of bacteria in the mucus layer is increased in
IBD [22], suggesting impaired mucosal barrier function. This
is consistent with the fact that many of the UC susceptibility
genes are related to mucosal barrier function. Furthermore,
bacteria that can degrade mucins in the mucus layer and utilize
it as an energy source, for example Ruminococcus gnavus and
Ruminococcus torques, are increased in IBD. These bacteria
help other bacteria reside in the mucus layer by providing
degraded mucins as nutrients.
IBD therapies targeting the gut microbiota
Fecal microbiota transplantation
Fecal microbiota transplantation (FMT) is a treatment to re-
store abnormal microbial composition of the gut by introduc-
ing fecal microbiota obtained from a healthy donor into a
diseased individual. The results of a randomized study to
compare FMT with antibiotics for recurrent Clostridium
difficile infection were striking [54]. Resolution ofC. difficile-
associated diarrhea was observed in 13 of 16 patients (81 %)
in the FMT group, compared with four out of 13 patients
(31 %) in the antibiotics group.
FMT has been highlighted as a treatment to correct
dysbiosis in IBD. The first implementation of FMT in UC
was reported in 1989 [55]. One of the authors of the paper
received FMT for his continuously active UC, resulting in
drug-free remission. A recent systematic review identified 18
UC patients without C. difficile infection who were treated
with FMT [56]. Thirteen out of the 18 patients experienced
disease resolution; however, selection bias should be consid-
ered because all of the cases were from case reports or small
case series.
Two prospective studies of FMT for adult UC pa-
tients were recently published [57, 58]. Both of these
studies longitudinally analyzed the change of bacterial
composition in FMT recipients. Unexpectedly, none of
the combined 11 patients in the two studies achieved
clinical remission after FMT. In contrast, a significant
change in the gut microbiota composition was observed
in most of the patients. One paper reported that the
successful colonization of donor microbiota was corre-
lated with clinical improvement in one patient, but the
other study did not confirm this finding. Both of the
papers reported that the alteration of gut microbiota was
temporary in most patients, suggesting the necessity of
periodically repeated transplantation to maintain the al-
tered gut microbiota.
A phase I trial of FMT for 10 pediatric UC patients with
mild-to-moderate activity has recently been completed,
reporting no serious adverse events and a high rate of clinical
response (79 %) within 1 week [59]. This result is in contrast
to the above-mentioned studies. One possible reason to ex-
plain this discrepancy is that a certain population of UC
patients, but not all, may benefit from FMT. Interestingly,
Angelberger et al. identified phylotypes that are indicative of
disease severity and FMT success, specifically over-
presentation of Enterobacteriaceae and under-repression of
Lachnospiraceae [57]. This is an important factor in selecting
a subgroup of UC patients that may be responsive to FMT.
Probiotics
Probiotics are preparations utilizing live bacteria that can be
beneficial to human health. Several reports have shown the
efficacy of various probiotic bacteria for IBD (Table 2). Effi-
cacy of probiotics was studied more extensively in UC than
CD. VSL#3 is a freeze-dried preparation containing eight
different lactic acid bacteria (Lactobacillus acidophilus,
L. bulgaricus, L casei, L. plantarum, Streptococcus
thermophilus, Bifidobacterium breve, B. infantis, and
B. longum). Two double-blinded placebo-controlled trials
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have shown the efficacy of VSL#3 in the prevention of
recurrence in patients with chronic relapsing pouchitis [60,
61]. Two randomized controlled clinical trials showed that
addition of VSL#3 to conventional therapy was more effica-
cious in remission induction in active UC patients [62, 63].
Another randomized controlled trial compared the efficacy of
addition of VSL#3 to mesalazine and steroids in 29 newly
diagnosed pediatric UC patients with addition of a placebo
[64]. The remission rates at 4 weeks were significantly higher
in the VSL#3 group (92.8 % (13/14)) than in the placebo
group (36.4 % (4/15)). Furthermore, the recurrence rates at
1 year were 36.4 % (3/14) and 73.3 % (11/15) in the VSL#3
and placebo groups, respectively. These results show that
VSL#3 is effective for induction of remission as well as its
maintenance in UC patients. The mechanism of the anti-
inflammatory effect of VSL#3 is not yet fully understood
but an increase in regulatory T cells in the gut and upregula-
tion of mucosal alkaline sphingomyelinase have been reported
[65].
Nissle 1917, a nonpathogenic E. coli strain, showed effica-
cy in maintenance of remission in UC equivalent to mesalazine
[66–68]. Nissle 1917 inhibits IL-8 production stimulated by
TNFα from the epithelial cells [69]. Lactobacillus GG can be
effective for maintenance of remission in UC patients [70], but
not in CD patients [71, 72]. A pilot study demonstrated that
Bifidobacterium longum/Synergy 1 improved intestinal inflam-
mation in active UC patients [73]. Bificobacteria-fermented
milk also demonstrated efficacy in induction and maintenance
of remission in UC patients [74, 75].
We reported that Clostridium butyricum (CB), which is
used as a probiotic for patients with functional gastrointestinal
disorders in a clinical setting, suppresses intestinal inflamma-
tion in murine IBDmodels [76]. CB potently induced the anti-
inflammatory cytokine IL-10 from colonic mucosal macro-
phages. This IL-10 production was dependent on the Toll-like
receptor 2/MyD88 pathway. The effect of CB was abolished
in IL-10-deficient mice, suggesting that the anticolitic effect of
CB was due to IL-10. Interestingly, heat-killed CB also in-
duced IL-10 from macrophages, strongly indicating that
bacterial-derived products are responsible for IL-10 induction.
A clinical trial to examine the anticolitic effect of CB in IBD
patients is warranted.
Table 2 Randomized controlled trials of probiotics for inflammatory bowel disease
Probiotics Disease Endpoint Groups and subject no. Duration Conclusion Ref.
VSL#3 UC Induction Conventional therapy+VSL#3, 77 12 weeks Effective [63]
Conventional therapy+placebo: 70
UC Induction Conventional therapy+VSL#3, 71 8 weeks Effective [62]
Conventional therapy+placebo, 73
UC Induction Steroid/mesalazine+VSL#3, 14 1 year Effective [64]
Maintenance Steroid/mesalazine+placebo, 15
Pouchitis Maintenance VSL#3, 20 9 months Effective [60]
Placebo, 20
Pouchitis Maintenance VSL#3, 20 12 months Effective [61]
Placebo, 16












Lactobacillus GG CD Maintenance Conventional therapy+Lactobacillus GG,
39
∼2 years Not effective [71]
Conventional therapy+placebo, 36







UC Induction Conventional therapy+BFM, 10 12 weeks Effective [74]
Conventional therapy+placebo, 10




UC Induction Bifidobacterium longum/Synergy 1, 9 1 month Effective [73]
Placebo, 9
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Closing remarks
The gut immune system is separated from an enormous num-
ber of bacteria only by a single layer of epithelial cells. It is
thus tempting to speculate that the gut microbiota is involved
in the pathophysiology of IBD. The advancement of next-
generation sequencing technology has revealed a range of
alterations of the gut microbiota in IBD. However, it remains
unclear whether the dysbiosis observed in IBD is a cause or a
consequence of intestinal inflammation. To answer this essen-
tial question, studies to examine longitudinal changes of the
microbiota in a large number of IBD patients, especially
newly diagnosed patients, are necessary. Furthermore, little
information is available to how dysbiosis regulates the gut
immune system. Understanding the complex relationship be-
tween the gut immune system and the microbiota should lead
to further elucidation of the pathogenesis of IBD and devel-
opment of curative treatments. Utilizing the gut microbiota as
a diagnostic tool or biomarker is also an attractive idea. To this
end, a disease-specific or activity-specific core microbiome
should be identified. The gut microbiota is composed not only
of bacteria but also of viruses and fungi. It is important to
include viruses and fungi in any investigation of the gut
microbiota. Furthermore, functional analysis of the gut micro-
biota in IBD is warranted. Because a majority of the gut
bacteria are unable to be cultured, gnotobiotic approaches will
be an important tool to investigate the function of the gut
microbiota. The gut microbiota represents a “gold mine” for
both clinical and basic IBD research.
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